Group 1 - MoonLake Immunotherapeutics' experimental drug for skin diseases showed disappointing late-stage clinical trial data, leading to a pre-market stock drop of over 86% [1] - UCB SA's stock rose by 20% following the news, with Financiere de Tubize SA, an investment tool of UCB's founder, also seeing a significant increase of 17% [1] - The key efficacy measure for MoonLake's sonelokimab in treating moderate to severe hidradenitis suppurativa was only 14% after placebo adjustment, compared to UCB's Bimzelx, which showed an 18% efficacy [1] Group 2 - Since Bimzelx's approval for psoriasis treatment at the end of 2023, UCB's stock has surged approximately 190% [4] - Hidradenitis suppurativa is a critical growth area for UCB, with 21% of Bimzelx's global net sales expected to come from this treatment by mid-2025 [4] - The market for hidradenitis suppurativa treatments is projected to grow from $2 billion currently to $15 billion by 2035, indicating a significant unmet need among patients [4]